Fair Pricing Coalition Commends ViiV Healthcare on the Price of Its New Drug Tivicay
August 13, 2013
While the Fair Pricing Coalition (FPC) believes that all HIV drugs are priced too high, we are satisfied that ViiV Healthcare's WAC price for Tivicay (dolutegravir), its new integrase inhibitor, is $14,105 per year, $1,037 more than its nearest competitor. FPC member Lynda Dee states, "We believe we can declare a victory here since ViiV followed our request, pricing Tivicay very close to its nearest competitor. ViiV could have priced Tivicay much higher based on its efficacy and improved dosing indication."
Given that Tivicay has proven in clinical studies to be more tolerable than many preferred HIV drugs, as well as potentially more potent, and given that it is a oncedaily pill at a low enough dosage to support its inclusion in single tablet regimens, we are pleased that the lower than expected price will make it easier for public payers of HIV drugs, such as the AIDS Drug Assistance Programs to more quickly add Tivicay to their formularies.View Full Article
Visit FPC's website to find out more about their activities and publications.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)